title: Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects.
abstract: Plasma levels of soluble CD27 (sCD27) are elevated in diseases characterized by T cell activation and are used as a marker of immune activation. We assessed the usefulness of determining plasma sCD27 as a marker for monitoring immune activation in HIV-1-infected patients treated with highly active antiretroviral therapy (HAART). A first cross-sectional examination of 68 HIV-1-infected and 18 normal subjects showed high levels of sCD27 in HIV-1 infection; plasma sCD27 was correlated to HIV-1 viraemia and inversely correlated to CD4+ T cell count. Twenty-six HIV-1-infected patients undergoing HAART were studied at baseline and after 6, 12, 18 and 24 months of therapy. Seven additional patients under HAART were analysed at baseline, during and after interruption of therapy. In the total population, HAART induced a significant and progressive reduction, but not a normalization, of plasma levels of sCD27 after 24 months. A full normalization of plasma sCD27 was observed in the virological responders (undetectable HIV-1 RNA at months 18 and 24) and also in patients with moderate immunodeficiency at baseline (CD4+ T cell count >200 cells/mm3). Changes in plasma neopterin paralleled the changes in sCD27 but only baseline sCD27 levels were predictive of a greater increase in CD4+ T cell count during the follow-up. Discontinuation of therapy resulted in a rapid increase of sCD27 plasma levels associated with viraemia rebound and drop in CD4+ T cell count. Our findings suggest that plasma sCD27 may represent an alternative and simple marker to monitor immune activation during potent antiretroviral therapy. HIV-1-induced immune activation can be normalized by HAART in successfully treated patients where the disease is not advanced.
authors.affiliation: Microbiology and Tumourbiology Centre, Karolinska Institutet, Stockholm, Sweden. Angelo.De.Milito@mtc.ki.se
authors.forename: A
authors.initials: A
authors.lastname: De Milito
authors.forename: S
authors.initials: S
authors.lastname: Aleman
authors.forename: R
authors.initials: R
authors.lastname: Marenzi
authors.forename: A
authors.initials: A
authors.lastname: Sonnerborg
authors.forename: D
authors.initials: D
authors.lastname: Fuchs
authors.forename: M
authors.initials: M
authors.lastname: Zazzi
authors.forename: F
authors.initials: F
authors.lastname: Chiodi
authors.forename: Fuchs
authors.initials: F
authors.lastname: D
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D015415:Biomarkers / Q000097:blood; D018791:CD4 Lymphocyte Count; D003430:Cross-Sectional Studies; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D008213:Lymphocyte Activation; D019798:Neopterin / Q000097:blood; D012367:RNA, Viral / Q000032:analysis; D013601:T-Lymphocytes / Q000276:immunology*; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7 / Q000097:blood*; D019562:Viral Load
chemical_list: D015415:Biomarkers; D012367:RNA, Viral; D018127:Tumor Necrosis Factor Receptor Superfamily, Member 7; D019798:Neopterin